Notably we observed the similar protective effect for CAD in both statins group and non-statins group in participant with very low Lp(a); we found that the risk of diabetes was enhanced in individuals on statins while the risk of NAFLD was attenuated in the context of statin use. This evidence concerns the gene LPA and metabolic dysfunction-associated steatotic liver disease.